Associations between change in blood pressure and functional outcome, early events and death: results from the Efficacy of Nitric Oxide in Stroke trial.


Journal

Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 28 6 2019
medline: 14 7 2020
entrez: 28 6 2019
Statut: ppublish

Résumé

High blood pressure (BP) is associated with a poor outcome after acute stroke. Early reduction in BP may be associated with fewer early adverse events and deaths, and improved functional outcome. Analyses used data from the Efficacy of Nitric Oxide in Stroke trial, a multicentre randomized single-masked and outcome-masked trial of glyceryl trinitrate vs. no glyceryl trinitrate in 4011 patients recruited within 48 h of an ischaemic or haemorrhagic stroke and with raised SBP (140-220 mmHg). Change in SBP from baseline to day 1 was categorized as: more than 15% decrease, 15-5% decrease, 5% decrease to 5% increase (no change - reference) and more than 5% increase. The primary outcome was functional outcome (modified Rankin scale) score at 90 days. Across all patients, both moderate (5-15%) and large (>15%) decreases in SBP were associated with beneficial shifts in the modified Rankin scale relative to patients with no change in BP: adjusted common odds ratio (OR) 0.81 [95% confidence interval (CI) 0.70-0.90] and OR 0.84 (95% CI 0.71-1.00), respectively. A moderate decrease in SBP was also associated with a lower risk of early adverse events, adjusted OR 0.69 (95% CI 0.52-0.90). Modest decreases in SBP in acute stroke appear to be associated with fewer early events and better long-term functional outcome.

Identifiants

pubmed: 31246895
doi: 10.1097/HJH.0000000000002154
pmc: PMC6727949
doi:

Substances chimiques

Vasodilator Agents 0
Nitroglycerin G59M7S0WS3

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2104-2109

Subventions

Organisme : Medical Research Council
ID : G0501797
Pays : United Kingdom

Références

Lancet. 2011 Feb 26;377(9767):741-50
pubmed: 21316752
Stroke. 2015 Dec;46(12):3362-9
pubmed: 26486868
Int J Stroke. 2006 Nov;1(4):245-9
pubmed: 18706028
Stroke. 2015 Nov;46(11):3194-201
pubmed: 26463698
Am J Emerg Med. 2007 Jan;25(1):32-8
pubmed: 17157679
Stroke. 2012 Aug;43(8):2108-14
pubmed: 22627991
Stroke. 2009 Jun;40(6):2098-103
pubmed: 19359649
Stroke. 2002 May;33(5):1315-20
pubmed: 11988609
JAMA. 2014 Feb 5;311(5):479-89
pubmed: 24240777
Stroke. 2016 Sep;47(9):2423-6
pubmed: 27444258
Acta Neurol Scand. 2002 Sep;106(3):142-7
pubmed: 12174173
Lancet Neurol. 2014 Apr;13(4):364-73
pubmed: 24530176
Int J Stroke. 2014 Apr;9(3):372-4
pubmed: 24588789
Stroke. 2011 Feb;42(2):491-3
pubmed: 21183747
Stroke. 2004 Feb;35(2):520-6
pubmed: 14726553
Lancet. 2015 Feb 14;385(9968):617-628
pubmed: 25465108

Auteurs

Else C Sandset (EC)

Department of Neurology.

Jason P Appleton (JP)

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.

Eivind Berge (E)

Department of Cardiology, Oslo University Hospital, Oslo, Norway.

Hanne Christensen (H)

Department of Neurology, Bispebjerg Hospital, Copenhagen, Denmark.

John Gommans (J)

Hawke's Bay Hospital, Hastings, New Zealand.

Kailash Krishnan (K)

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.

George Ntaios (G)

Department of Medicine, University of Thessaly, Greece.

Stephen Phillips (S)

Division of Neurology, Department of Medicine, Dalhousie University, Halifax, Canada.

Stuart Pocock (S)

London School of Hygiene and Tropical Medicine, London, UK.

Nikola Sprigg (N)

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.

Lisa J Woodhouse (LJ)

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.

Philip M Bath (PM)

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH